Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
80 hedge funds and large institutions have $160M invested in Repros Therapeutics Inc. in 2014 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 13 closing their positions.
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
27% more call options, than puts
Call options by funds: $7.36M | Put options by funds: $5.78M
7% more funds holding
Funds holding: 75 → 80 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $199M → $160M (-$38.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.86M |
| 2 |
RA
Royce & Associates
New York
|
+$2.14M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$1.41M |
| 4 |
AGCJ
Alden Global Capital (Jersey)
St. Helier,
Jersey
|
+$1.31M |
| 5 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$10M |
| 2 |
PC
Paulson & Co
New York
|
-$9.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$6.64M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$6.46M |
| 5 |
State Street
Boston,
Massachusetts
|
-$6.25M |
RPRX Hedge Fund Activity: Q4 2014 in Review
80 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q4 2014, worth a combined $160M — down 20% from $199M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RPRX positions and 13 closed out — a net gain of 6 holders — while 29 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $4.86M. The largest seller was Oracle Investment Management, exiting entirely with an estimated $10M sold.
- 80 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q4 2014, up from 75 in Q3 2014.
- Funds reported $160M of Repros Therapeutics Inc. stock for Q4 2014, down 20% quarter-over-quarter.
- 19 funds opened new Repros Therapeutics Inc. positions in Q4 2014 and 13 closed out, a net change of +6 holders.
- The largest Repros Therapeutics Inc. buyer in Q4 2014 was Fidelity Investments, an estimated $4.86M added.
- The largest Repros Therapeutics Inc. seller in Q4 2014 was Oracle Investment Management, an estimated $10M sold.
Based on aggregated 13F filings for Q4 2014.